The Phase II study of rF-TRICOM in patients with metastatic melanoma aims to evaluate the safety and efficacy of intratumoral vaccine therapy. Given the increasing incidence of melanoma and the limited treatment options for advanced stages, this asset has potential commercial value in a competitive landscape dominated by immunotherapies such as checkpoint inhibitors. The trial's focus on patients with detectable tumor-associated T cells may position it favorably in the market, particularly if it demonstrates superior local and systemic responses compared to existing therapies. However, the termination of the study may raise concerns regarding the viability of this approach and necessitate further diligence on the reasons for discontinuation and the implications for future development.